NCT02503423 2026-03-20
Phase 1-2 Study of ASTX660 in Subjects With Advanced Solid Tumors and Lymphomas
Taiho Oncology, Inc.
Phase 1/2 Active not recruiting
Taiho Oncology, Inc.
Institute of Cancer Research, United Kingdom
National Cancer Institute (NCI)